All Photos(1)

Documents

COO/COA

1379401

USP

Meloxicam

Name: Meloxicam
Brand: USP

United States Pharmacopeia (USP) Reference Standard

Synonym(s):

4-Hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide

Sign Into View Organizational & Contract Pricing

All Photos(1)

About This Item

Empirical Formula (Hill Notation):

C₁₄H₁₃N₃O₄S₂

CAS Number:

71125-38-7

Molecular Weight:

351.40

UNSPSC Code:

41116107

NACRES:

NA.24

grade

pharmaceutical primary standard

API family

meloxicam

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

InChI

1S/C14H13N3O4S2/c1-8-7-15-14(22-8)16-13(19)11-12(18)9-5-3-4-6-10(9)23(20,21)17(11)2/h3-7,19H,1-2H3,(H,15,16)/b13-11+

InChI key

DWMREKMVXIFPFM-ACCUITESSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

Analytical Reference Standards

Pharmacopeia & Metrological Institute Standards

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Meloxicam USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:

Meloxicam Oral Suspension
Meloxicam Tablets

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.

Other Notes

Sales restrictions may apply.

related product

Product No.

Description

Pricing

1379423

1379412

1379445

1379434

PHR2501

PHR2131

Meloxicam Impurity D

PHR2327

Meloxicam Impurity C, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2500

PHR2502

PHR2503

Meloxicam Impurity E, Pharmaceutical Secondary Standard; Certified Reference Material

Pictograms

GHS06

Signal Word

Danger

Hazard Statements

H301

Precautionary Statements

P264 - P270 - P301 + P310 - P405 - P501

Hazard Classifications

Acute Tox. 3 Oral

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

A review of the clinical pharmacokinetics of meloxicam.

D Türck et al.

British journal of rheumatology, 35 Suppl 1, 13-16 (1996-04-01)

Meloxicam is a new preferential cyclooxygenase-2 (COX-2) inhibitor currently for the treatment of osteoarthritis and rheumatoid arthritis. Its pharmacokinetic profile is characterized by a prolonged and almost complete absorption and the drug is > 99.5% bound to plasma proteins. Meloxicam

Pharmacology of meloxicam, a new non-steroidal anti-inflammatory drug with an improved safety profile through preferential inhibition of COX-2.

G Engelhardt

British journal of rheumatology, 35 Suppl 1, 4-12 (1996-04-01)

This review focuses on the key pharmacological findings with a new NSAID, meloxicam. Unlike established NSAIDs, it preferentially inhibits inducible COX-2 in guinea-pigs peritoneal macrophages and human COX-2 in COS cells. Compared with other NSAIDs, meloxicam is the most potent

[Meloxicam (Movalis)].

Dusanka Martinović Kaliterna

Reumatizam, 54(2), 81-82 (2008-03-21)

Meloxicam: selective COX-2 inhibition in clinical practice.

D E Furst

Seminars in arthritis and rheumatism, 26(6 Suppl 1), 21-27 (1997-06-01)

Nonsteroidal antiinflammatory drugs (NSAIDs) exert their actions by inhibiting cyclooxygenase (COX). It has recently been postulated that NSAIDs' antiinflammatory efficacy arises from inhibition of the COX-2 isoform of cyclooxygenase, whereas inhibition of the COX-1 isoform produces the troublesome and sometimes

[Pharma-Clinics. The drug of the month. Meloxicam (Mobic)].

A J Scheen

Revue medicale de Liege, 52(4), 309-311 (1997-04-01)

View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service